Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $4.00 million. The enterprise value is $2.82 million.
Important Dates
The next estimated earnings date is Friday, May 2, 2025, before market open.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 2.56 million shares outstanding. The number of shares has increased by 1,468.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.56M |
| Shares Change (YoY) | +1,468.08% |
| Shares Change (QoQ) | +101.93% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.60% |
| Float | 2.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.10 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.75 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.75 |
Financial Efficiency
Return on equity (ROE) is -88.14% and return on invested capital (ROIC) is -81.03%.
| Return on Equity (ROE) | -88.14% |
| Return on Assets (ROA) | -45.41% |
| Return on Invested Capital (ROIC) | -81.03% |
| Return on Capital Employed (ROCE) | -94.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$551,714 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -312,981 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.30% in the last 52 weeks. The beta is 1.71, so BDRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -92.30% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 7.20 |
| Relative Strength Index (RSI) | 44.22 |
| Average Volume (20 Days) | 1,222,904 |
Short Selling Information
| Short Interest | 68,470 |
| Short Previous Month | 62,096 |
| Short % of Shares Out | 2.67% |
| Short % of Float | 2.97% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | -6.81M |
| Operating Income | -11.52M |
| Pretax Income | -9.56M |
| Net Income | -7.17M |
| EBITDA | -11.37M |
| EBIT | -11.52M |
| Earnings Per Share (EPS) | -$14.48 |
Full Income StatementBalance Sheet
The company has $2.09 million in cash and $910,149 in debt, giving a net cash position of $1.18 million or $0.46 per share.
| Cash & Cash Equivalents | 2.09M |
| Total Debt | 910,149 |
| Net Cash | 1.18M |
| Net Cash Per Share | $0.46 |
| Equity (Book Value) | 10.42M |
| Book Value Per Share | 15.58 |
| Working Capital | 4.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.35 million and capital expenditures -$11,267, giving a free cash flow of -$16.35 million.
| Operating Cash Flow | -15.35M |
| Capital Expenditures | -11,267 |
| Free Cash Flow | -16.35M |
| FCF Per Share | -$6.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |